Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizoaffective Clear all
Completed Phase 2 Interventional

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCT00139906
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

NCT00547118
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension, Smoking
Interventions
Rimonabant, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NCT07043803
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
Interventions
Reduction of anticholinergic medication
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Altoona, Pennsylvania • Erie, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders

NCT02930005
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Meclofenamic acid, Pentosan polysulfate sodium
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers

NCT02386605
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Long-acting Injectable Medications for Schizophrenia

NCT01136772
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
haloperidol decanoate, paliperidone palmitate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

NCT00211302
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Clinical Trial of AVL-3288 in Schizophrenia Patients

NCT02978599
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
AVL-3288, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
adjunctive treatment with buspirone, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Obstructive Sleep Apnea Treatment in Serious Mental Illness

NCT05457127
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Obstructive Sleep Apnea of Adult
Interventions
Automatic Positive Airway Pressure (APAP)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

NCT01568203
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode

NCT02267070
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Case management and supportive psychotherapy, Family psychoeducation, Cognitive training, Aerobic exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

NCT00130923
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
Interventions
Risperidone Long Acting, oral risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Kansas City, Missouri • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150
View directory record Official record
Conditions
Schizophrenia
Interventions
Targeted cognitive training, Computer control, Bridging groups, Health and wellness groups
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
New Haven, Connecticut • Atlanta, Georgia • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Lifestyle Modification for Weight Loss in Schizophrenia

NCT00990925
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Nutritional Lifestyle Modification Group, Usual Care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 17, 2026, 4:08 AM EDT